SCHEMBL31657083

SCHEMBL31657083

Nc1cccc(Sc2cnc(N3CCC4(CC3)Cc3ccccc3C4)cn2)c1Cl

nearest known ligand 0.72

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ PTPN11 Q06124 20/20 0.72
▸ KCNH2 Q12809 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19785449 0.88 PTPN11 (0.77) PTPN11KCNH2
SCHEMBL28506515 0.87 PTPN11 (0.65) PTPN11KCNH2
SCHEMBL20347136 0.85 PTPN11 (0.85) PTPN11KCNH2
SCHEMBL31657077 0.84 PTPN11 (0.52) PTPN11KCNH2
SCHEMBL18328265 0.84 PTPN11 (1.00) PTPN11
SCHEMBL31096530 0.84 PTPN11 (0.66) PTPN11KCNH2
SCHEMBL22770262 0.84 PTPN11 (0.66) PTPN11KCNH2
SCHEMBL30141213 0.83 PTPN11 (0.75) PTPN11KCNH2
SCHEMBL28648881 0.83 PTPN11 (0.82) PTPN11
SCHEMBL28512254 0.83 PTPN11 (0.50) PTPN11KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250223285-A1 NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS JACOBIO PHARMACEUTICALS CO LTD (CN) 2025-07-10 — — US claimed
US-20250223285-A1 NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS JACOBIO PHARMACEUTICALS CO LTD (CN) 2025-07-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250223285-A1 NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS PTPN5, PTPN1, PTPRJ PTPN11 13/4885KCNH2 4068/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback